Home of InterVac   International Vaccine Centre

Business Development - Commercial success

Overview of Business Development

 

VIDO-InterVac has an international track record for vaccine R&D targetting infectious diseases of animals and humans that includes:

 

  • more than 80 U.S. patents.

 

  • technology commercialized into 8 vaccines, 6 that were world firsts.

 

 

We offer an exceptional user services program, with competitive rates and full service research capabilities for Containment Level 2 and 3 organisms. 

 

  • Existing facilities include modern virology, immunology, bacteriology and biochemistry labs and a 160-acre research station

.

  • InterVac adds 145,000 sq ft of vaccine research space, including CL3 research capability, to our existing facilties.

 

 

 

VIDO-InterVac welcomes inquiries about new research collaborations and partnerships.  

 

  • Inquiries should be directed to Dr. Paul Hodgson, Associate Director for Business Development at (306) 966-1523 or paul.hodgson@usask.ca

 


About the Business Development Team

 

Associate Director - Business Development: Dr. Paul Hodgson

Corporate Communications Manager:  Shirley Toms

Industry Technical Groups Coordinator:  Sherri Hueser

IT Support Specialist:  Marc Buchmann

 


Communications

 

VIDO-InterVac communications staff provide support through:

  • production of internal and external publications
  • website development and maintenance
  • media and community relations
  • strategic communications

 

Inquiries about communications should be directed to Shirley Toms, Corporate Communication Manager at (306) 966-7483 or shirley.toms@usask.ca


Project Management

 

VIDO-InterVac project management and coordination staff provide support through:

  • project plans for research projects
  • coordination with external collaborators
  • development of reports, summaries and presentations 
  • coordination of industry liaison